Chimeric NK receptor and methods for treating cancer
US8252914B2 · kind B2 · utility
115Cited by
2References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 8, 2011 |
| Grant date | Aug 28, 2012 |
| Priority date | — |
| Expiry date | Jun 8, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2239/48
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.